GlassScriptPhysician profile
Tambra Daniels
NPI 1376012070
$1,382.69
in general payments reported to CMS, 2019-2025
18 companies · $585 in 2025
The $585 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.46 · 2024: $781 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $188.02 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $147.47 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $146.83 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $134.81 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $134.02 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.90 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $94.39 | 2024-2025 | Invega Sustenna |
| Indivior INC. | $88.46 | 2024-2025 | Sublocade, Perseris |
| Gilead Sciences, INC. | $53.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.84 | 2024 | Trintellix |
| Novo Nordisk INC | $43.91 | 2025 | Wegovy |
| Exact Sciences Corporation | $40.58 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $37.37 | 2024 | Rexulti |
| Seqirus USA INC | $25.34 | 2025 | Flucelvax |
| Pfizer INC. | $22.62 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $15.88 | 2024 | Adzenys Xr-Odt |
| Recor Medical INC | $13.80 | 2025 | Paradise Ultrasound Renal Denervation System |
| Lundbeck LLC | $13.73 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tambra Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.